Leukemia

Article	Citations
Quantifying measurable residual disease correctly	3079
Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma	2804
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis	198
Correction: Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15	172
Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study	162
MCL1 as a therapeutic vulnerability in Burkitt lymphoma	126
CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL	112
Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide	108
Clonal medicine targeting DNA damage response eradicates leukemia	101
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study	101
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial	98
The potential of cell-free DNA to reveal the molecular profiles of Langerhans cell histiocytosis and Erdheim–Chester disease in adults	97
DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells	95
Cohesin mutations in acute myeloid leukemia	93
Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia	89
Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia	81
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia	80
Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core	79
The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH)	76
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)	74
The 5th edition of the WHO classification of haematolymphoid tumors: comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH)	74
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial	73
Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis	73
Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms	72
Diverse mechanisms of leukemogenesis associated with PAX5 germline mutation	70

Bidirectional anti-tumor and immunological strategies by targeting GARP–TGF-β axis in adult T-cell leukemia/lymphoma	70
Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms	65
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies	63
Key regulatory roles of PRDM1 in human NK-cell differentiation and activation	62
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase	62
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9	61
Real life evaluation of AlphaMissense predictions in hematological malignancies	61
Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication	61
Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation	59
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma	59
Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma	58
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche	58
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation	56
Real-time genomic characterization of pediatric acute leukemia using adaptive sampling	56
An MDM2 degrader for treatment of acute leukemias	55
Nucleic acid therapeutics as differentiation agents for myeloid leukemias	55
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries	55
Essential role of Dhx16-mediated ribosome assembly in maintenance of hematopoietic stem cells	54
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial	52
Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 2009	51
Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors	48
Rheumatoid arthritis and the risk of hematologic malignancies: a nationwide cohort study	48
Combining lenalidomide with erythropoiesis stimulating agents: a party of one	46
Correction: Mitochondrial regulation of GPX4 inhibition–mediated ferroptosis in acute myeloid leukemia	46
A bioinformatics perspective on molecular classification of diffuse large B-cell lymphoma	44
Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia	44
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials	44
miR-196b-Oct1/2 axis regulates DNMT3A-mutant AML pathogenesis	43
Response to Pfirrmann et al.’s comment on How should we interpret conclusions of TKI-stopping studies	43
Hemolytic versus malproductive anemia in large granular lymphocytic leukemia	43
Sirolimus is effective for refractory/relapsed/intolerant acquired pure red cell aplasia: results of a prospective single-institutional trial	43
Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)/FUS::ERG	43
Transient regulation of RNA methylation in human hematopoietic stem cells promotes their homing and engraftment	43
Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia	41
Znf687 recruits Brd4-Smrt complex to regulate gfi1aa during neutrophil development	41
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia	41
DNA demethylating agents for chemoprevention of oncovirus-associated leukemogenesis	41
RNAseqCNV: analysis of large-scale copy number variations from RNA-seq data	41
Does everyone with newly-diagnosed, untreated acute myeloid leukaemia need remission-induction chemotherapy before advancing to a transplant?	41
CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia	40
Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia	40
Oncogenic dependency on SWI/SNF chromatin remodeling factors in T-cell acute lymphoblastic leukemia	39
Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia	39
Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation	39
Ppm1d truncating mutations promote the development of genotoxic stress-induced AML	39
A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy	38
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression	38
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia	38
Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL	37
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN)	37

METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4	37
CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL	37
Measurable residual disease (MRD)-testing in haematological and solid cancers	37
STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells	37
Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions	36
Impaired binding affinity of YTHDC1 with METTL3/METTL14 results in R-loop accumulation in myelodysplastic neoplasms with DDX41 mutation	36
PHF6 suppresses self-renewal of leukemic stem cells in AML	36
Whole-genome sequencing of myeloproliferative neoplasms revealed dynamic clonal changes in the fibrotic or leukemic transformation and novel FOXP1 mutations in the fibrotic transformation	35
CLL cell-derived exosomes alter the immune and hematopoietic systems	34
Correction: Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks	34
Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms	34
CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study	34
New criteria for estimating numbers of CD34-positive cells in a graft needed for posttransplant bone marrow recovery	34
Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia—a Grand Ouest Against Leukemia (GOAL) study	33
5-Azacytidine and decitabine induce C > G transversions in both murine and human cells	33
RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort	33
BRAFV600E promotes DC3/monocyte differentiation in human gene-engineered HSPCs and causes multisystem histiocytosis	31
Second versus first wave of COVID-19 in patients with MPN	31
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study	30
Progressive T cell defects correlate with disease outcome in high-count monoclonal B-cell lymphocytosis	30
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients	30
How should we interpret conclusions of TKI-stopping studies	30
MYC, mitochondrial metabolism and O-GlcNAcylation converge to modulate the activity and subcellular localization of DNA and RNA demethylases	30
The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms	29
A primary hierarchically organized patient-derived model enables in depth interrogation of stemness driven by the coding and non-coding genome	29
TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma	29
Functions of the native NPM1 protein and its leukemic mutant	29
PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL	29
Germline PTPN13 mutations in patients with bone marrow failure and acute lymphoblastic leukemia	29
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib	28
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study	28
Targeting proteostasis in multiple myeloma through inhibition of LTK	28
The exon-junction complex helicase eIF4A3 holds therapeutic potential in acute myeloid leukemia	28
The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia	28
Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia	28
Emerging T-cell lymphomas after CAR T-cell therapy	28
Base edited “universal” donor CAR T-cell strategies for acute myeloid leukaemia	28
Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells	27
Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms	27
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis	27
Mitochondrial regulation of GPX4 inhibition–mediated ferroptosis in acute myeloid leukemia	27
Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm	27
Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib	27
Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis	27
Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose	27
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants	27
Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-	27
Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study	26
Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis	26
Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group	26
Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment	26
Immunogenetics in hematopathology and hematology: why a common language is important	26
Cre recombinase promotes leukemogenesis in the presence of both homozygous and heterozygous FLT3-ITD	26
A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML	25
Correction: Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML	25
A pro B cell population forms the apex of the leukemic hierarchy in Hoxa9/Meis1-dependent AML	25
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia	25
How fast does leukemia progress?	25
Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis	25
What is radiation-induced acute myeloid leukaemia/can it be accurately identified?	25
A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia	24
KDM6B protects T-ALL cells from NOTCH1-induced oncogenic stress	24
Harnessing upregulated E-selectin while enhancing SDF-1α sensing redirects infused NK cells to the AML-perturbed bone marrow	24
Relationship among three common hematological premalignant conditions	24
T-cell diversity and exclusion of blood-derived T-cells in the tumor microenvironment of classical Hodgkin Lymphoma	24
Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma	24
Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia	24
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics	24
S1P-S1PR3-RAS promotes the progression of S1PR3hi TAL1+ T-cell acute lymphoblastic leukemia that can be effectively inhibited by an S1PR3 antagonist	24
EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma	24
Single-cell RNA sequencing of a new transgenic t(8;21) preleukemia mouse model reveals regulatory networks promoting leukemic transformation	24
Sulforaphane promotes natural killer cell-mediated anti-tumor immune responses partially via cGAS-STING pathway in classical Hodgkin lymphoma	24
NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia	23
Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction	23
Leukemogenesis occurs in a microenvironment enriched by extracellular microvesicles/exosomes: recent discoveries and questions to be answered	23
Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies	23
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY	23
Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP diet and health study	23
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial	23
Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma	23

Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632)	23
High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease	23
Inhibition of the m6A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia	23
Are real world data real world data?	23
Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia	23
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer	23
Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia	23
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms	23
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study	23
The histone demethylase KDM5C functions as a tumor suppressor in AML by repression of bivalently marked immature genes	23
Correction: Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway	22
Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukaemia	22
Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements	22
Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations	22
Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival	22
Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures	22
ADH5/ALDH2 dehydrogenases and DNA polymerase theta protect normal and malignant hematopoietic cells from formaldehyde challenge: therapeutic implications	22
Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period	22
Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia	22
NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation	22
A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses	22
Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms	22
Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach	22
miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease	22
Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma	22
Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia	22
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)	22
Cerebrospinal fluid proteomics exerts predictive potential for immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR-T cell therapy	22
Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission	21
LIN28B promotes differentiation of fully transformed AML cells but is dispensable for fetal leukemia suppression	21
Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia	21
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice	21
Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia	21
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment	21
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study	21
Association between CEP72 genotype and persistent neuropathy in survivors of childhood acute lymphoblastic leukemia	21
Targeting ZDHHC21/FASN axis for the treatment of diffuse large B-cell lymphoma	21
Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma	21
Survival with chronic myeloid leukaemia after failing milestones	21
Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia	20
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia	20
Co-variates associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phase	20
Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?	20
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms	20
Skin lesions, arthritis, chondritis, and cytopenias	20
GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma	20
Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies	20
High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia	20
Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia	20
Glucose uptake capacity of leukaemia cells in vitro correlates with response to induction therapy in acute myeloid leukaemia	19
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working p	19
Overt and covert genetic causes of pediatric acute lymphoblastic leukemia	19
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma	19
Correspondence to “A novel lncRNA SNHG29 regulates EP300-related histone acetylation modification and inhibits FLT3-ITD AML development”	19
Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis	19
Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis	19
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis	19
Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations	19
Molecular mechanisms underlying transformation of large granular lymphocytic leukemia to high-grade T-cell lymphoma	19
A genome-wide association study identifies an African-specific locus on chromosome 21q22.12 associated with Burkitt lymphoma risk and survival	19
Intensive post-remission therapy does not decrease relapse after allotransplants for acute myeloid leukaemia in 1st remission and should not be given	19
What do atomic bomb survivors teach us about therapy-free remission in people with chronic myeloid leukaemia?	19
Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group	19
Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia	19
Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes	19
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia	19
Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients	19
PML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias	18
Updates of the ERIC recommendations on how to report the results from immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia	18
Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation	18
Correction: Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia	18
MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs’ patients	18
P4HA2 hydroxylates SUFU to regulate the paracrine Hedgehog signaling and promote B-cell lymphoma progression	18
Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells	18
Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease	18
A DNA methylation database of human and mouse hematological malignancy cell lines	18
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance	18
Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia	18
High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL	18
Acute myeloid leukemia: does sex matter?	18
Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition	18
Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection	18
SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms	17
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community	17
The landscape of RNA-chromatin interaction reveals small non-coding RNAs as essential mediators of leukemia maintenance	17
OGG1 activation improves T cell resilience to oxidative stress after allo-SCT and T cell engager exposure	17
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)	17
Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases	17
Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis	17
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients	17
Analysis of autophagy in DLBCL reveals subtype-specific differences and the preferential targeting of ULK1 inhibition in GCB-DLBCL provides a rationale as a new therapeutic approach	17
High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance	17
Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes	17
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML	17
Molecular profiling and risk stratification in solitary bone plasmacytoma	17